| P2093 | author name string | Hiroaki Kitano | |
| P2860 | cites work | Involvement of chemokine receptors in breast cancer metastasis | Q24290909 |
| | Negative control of p53 by Sir2alpha promotes cell survival under stress | Q24291828 |
| | Metapopulation dynamics and spatial heterogeneity in cancer | Q24538673 |
| | Targeting HIF-1 for cancer therapy | Q27860504 |
| | A genetic model for colorectal tumorigenesis | Q27860582 |
| | Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase | Q27860668 |
| | Stem cells, cancer, and cancer stem cells | Q27860878 |
| | Surfing the p53 network | Q28032484 |
| | Genetic instabilities in human cancers | Q28131826 |
| | A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage | Q28138556 |
| | Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects | Q28200181 |
| | Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene | Q28202069 |
| | Putting tumours in context | Q28207789 |
| | The complexity of p53 modulation: emerging patterns from divergent signals | Q28284854 |
| | Sustained loss of a neoplastic phenotype by brief inactivation of MYC | Q74413944 |
| | Extensive cytogenetic heterogeneity in a benign retroperitoneal schwannoma | Q95721482 |
| | Error and attack tolerance of complex networks | Q29547268 |
| | Hypoxia--a key regulatory factor in tumour growth | Q29547318 |
| | The large-scale organization of metabolic networks | Q29547498 |
| | Systems biology: a brief overview | Q29547514 |
| | Cancer. Addiction to oncogenes--the Achilles heal of cancer | Q29614243 |
| | Computational systems biology | Q29616655 |
| | Stochastic mechanisms in gene expression | Q29617407 |
| | Robustness in bacterial chemotaxis | Q29617495 |
| | Robustness in simple biochemical networks | Q29617496 |
| | The segment polarity network is a robust developmental module | Q29618600 |
| | Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 |
| | The microenvironment of the tumour-host interface | Q29620375 |
| | Human Sir2 and the 'silencing' of p53 activity | Q30309900 |
| | Aneuploidy vs. gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy | Q30587566 |
| | Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer | Q33357640 |
| | A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance | Q33377470 |
| | It's a noisy business! Genetic regulation at the nanomolar scale | Q33546905 |
| | Genetic instability and darwinian selection in tumours | Q33804007 |
| | Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis | Q33900139 |
| | MDM2 oncogene as a novel target for human cancer therapy | Q33902429 |
| | Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs | Q34060806 |
| | Tumor reversion: Correction of malignant behavior by microenvironmental cues | Q34103266 |
| | Complexity and robustness | Q34138870 |
| | Error catastrophe and antiviral strategy | Q34153584 |
| | How does calorie restriction work? | Q34175282 |
| | Tumors are unique organs defined by abnormal signaling and context | Q34231927 |
| | Biological consequences of tumor hypoxia | Q34275624 |
| | Multiple mutations and cancer | Q34327554 |
| | Solitary cancer cells as a possible source of tumour dormancy? | Q34341754 |
| | T-cell immunity in the induction and maintenance of a tumour dormant state | Q34341769 |
| | "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally | Q34369829 |
| | A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants | Q34488592 |
| | Reverse engineering of biological complexity | Q34548755 |
| | Chemokines: agents for the immunotherapy of cancer? | Q34576416 |
| | Tumor progression: a brief historical perspective | Q34766105 |
| | Hypoxia-induced pathways in breast cancer | Q34872665 |
| | Engineered gene circuits. | Q34997456 |
| | Control, exploitation and tolerance of intracellular noise | Q34997459 |
| | T cell memory, anergy and immunotherapy in breast cancer | Q35015669 |
| | Cancer chronotherapy: principles, applications, and perspectives | Q35030286 |
| | Linking chromatin function with metabolic networks: Sir2 family of NAD(+)-dependent deacetylases | Q35040959 |
| | Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans | Q35044170 |
| | Promises and pitfalls of anti-angiogenic therapy in clinical trials | Q35076995 |
| | Cancer immunotherapy: the past, the present and the future | Q35083647 |
| | Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators | Q35100585 |
| | The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics. | Q35108617 |
| | Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study | Q35268497 |
| | Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. | Q35581806 |
| | Tumor hypoxia: a target for selective cancer therapy | Q35602696 |
| | Robust perfect adaptation in bacterial chemotaxis through integral feedback control | Q35689729 |
| | Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor | Q36312026 |
| | Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85) | Q36430928 |
| | Multidrug resistance (mdr) genes in human cancer | Q36495579 |
| | Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells | Q38341890 |
| | Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein | Q38352366 |
| | Toward a chronotherapy of neoplasia: Tolerance of treatment depends upon host rhythms | Q39931271 |
| | Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. | Q40633683 |
| | Viral quasispecies. | Q40828271 |
| | Cancer dormancy: opportunities for new therapeutic approaches | Q41463105 |
| | Robustness of a gene regulatory circuit | Q41842616 |
| | Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling | Q42478267 |
| | Roots of clinical resistance to STI-571 cancer therapy | Q43744914 |
| | Robustness as a measure of plausibility in models of biochemical networks | Q44036135 |
| | Cytogenetic and molecular mechanisms of resistance to imatinib | Q44463519 |
| | Bifurcation analysis of a model of mitotic control in frog eggs | Q45114625 |
| | Aneuploidy theory explains tumor formation, the absence of immune surveillance, and the failure of chemotherapy | Q45288287 |
| | Simulation of prokaryotic genetic circuits | Q46714216 |
| | Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. | Q50626711 |
| | Robust oscillations within the interlocked feedback model of Drosophila circadian rhythm. | Q52061014 |
| | A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity. | Q52548391 |
| | Robustness, flexibility, and the role of lateral inhibition in the neurogenic network. | Q52596238 |
| | Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. | Q53397513 |
| | Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. | Q53431099 |
| | Somatic recombination redux. | Q55036287 |
| | Cancer robustness: Tumour tactics | Q59086311 |
| | Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells | Q62498340 |
| | Angiostatin induces and sustains dormancy of human primary tumors in mice | Q71101907 |
| | Tumour dormancy: not so sleepy after all | Q71802890 |
| | Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression | Q71802927 |
| | Circadian clocks limited by noise | Q73412329 |
| | Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group | Q73977659 |
| P433 | issue | 3 | |
| P304 | page(s) | 227-235 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | Cancer as a robust system: implications for anticancer therapy | |
| P478 | volume | 4 | |